NAD+
NAD+ is an essential redox coenzyme that peptide vendors sell in buffered injectable form; the 19 captured community reports center on energy and vitality, with roughly two-thirds of those users describing positive outcomes. A single clinician source suggests daily subcutaneous injections of 100–200 mg taken in the morning and cycled for four to eight weeks, though actual community dose reporting remains sparse. The off-label evidence base is thinner than the discourse suggests, and most exploratory indications lack posted trial results.
Research Evidence
Evidence shape
NAD+ reaches the highest evidence tier, with Phase 3 trials and one blinded study posting a −0.5 percentage predicted FEV1 result in Cystic Fibrosis. Twenty-seven registered trials enroll a combined 340 participants across five sponsors, yet 21 of the 25 mapped indications are single-trial entries, 19 are thin or exploratory, and one is animal-only. Four more indications—including heart failure—have registered trials with no posted results, leaving Cystic Fibrosis as the sole indication with reported trial data.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How NAD+ is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Timing
- unspecified
- Cycle
- unspecified
5 completed trials identified; trial dosing not reliably extracted from registry data.
- Frequency
- daily
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 100 mg–200 mg daily subQ (1 source).
No structured protocol details captured for this tier yet.
Anecdotal reports primarily focus on energy and vitality (66.7% positive from 18 reports) and disease support (71.4% positive from 7 reports). Specific dosage information from community posts is not consistently available.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for NAD+, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.